CIP
MRNA icon

Convergence Investment Partners’s Moderna MRNA Stock Holding History

Convergence Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,100
Closed -$279K – 239
2021
Q4 		$279K Sell
1,100
-402
-27% -$118K 0.14% 144
2021
Q3 		$578K Buy
1,502
+136
+10% +$50.2K 0.31% 89
2021
Q2 		$321K Sell
1,366
-842
-38% -$150K 0.14% 157
2021
Q1 		$289K Buy
+2,208
New +$320K 0.13% 158

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Convergence Investment Partners's MRNA Position: Q1 2022 in Review

Convergence Investment Partners sold out of Moderna (MRNA) in Q1 2022, closing a stake of 1,100 shares — an estimated $279K sold.

Convergence Investment Partners first reported a position in MRNA in Q1 2021 and held it in 4 quarters. The position peaked at $578K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Convergence Investment Partners reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Convergence Investment Partners sold 1,100 Moderna shares in Q1 2022, an estimated $279K.
  • Convergence Investment Partners first reported a position in Moderna in Q1 2021 and held it in 4 quarters.
  • Convergence Investment Partners's Moderna position peaked at $578K in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Convergence Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.